!

COVID-19 Response 

Access our COVID-19 Response homepage, with more information and resources during the COVID-19 pandemic, including what to do if you’re experiencing symptoms.

Baylor College of Medicine

DECIST: Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma (H-42434)

Description

Content

The primary objective of this phase 1, first in man trial is to determine the safety, toxicity, and feasibility of delivering autologous dendritic cells (DCs) loaded with pancreatic adenocarcinoma lysate plus mRNA to pancreatic cancer patients as adjuvant therapy following completion of standard chemotherapy.

Patients will first complete standard treatment for pancreatic adenocarcinoma which is surgically resectable and then within 3 months of finishing chemotherapy, they will have three doses of the dendritic cell vaccine by perinodal injection using ultrasound guidance.

For more information: https://clinicaltrials.gov/ct2/show/NCT04157127.

Contact

Dr. Benjamin Musher

Phone 1: 713–798–4292

IRB: H-42434

Status:

Active

Created:

Back to topback-to-top